Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC.RXRX · Entity 1008 | Chief Medical Officer | May 16, 2022 | May 18, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
RECURSION PHARMACEUTICALS, INC.
Report date May 16, 2022 · Filed May 18, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 121,110 |
Reported balance
After 2022-05-16 transaction · row 1
1 source rowRow 1 · 2022-05-16 · Tax withholding · Disposed 832 · Balance 121,110 F1: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 16, 2022 Filed May 18, 2022 23:19 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 832 | $5.67 | $4,717.44 |
DisclosureSEC source: 0001209191-22-030255 · doc4.xml · nonDerivative · entry 1 Doyle Ramona · CIK 0001856069 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,110 F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 20:06 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,072 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001209191-22-022310 · doc4.xml · derivative · entry 2 Doyle Ramona · CIK 0001856069 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 669,356 Underlying: Class A Common Stock · 669,356 shares Expires 2030-12-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Twenty-Five percent (25%) of the 750,000 shares originally subject to the award shall vest one year after December 31, 2020, or the Vesting Commencement Date, and one-forty-eighth (148th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 20:06 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionClass A Common Stock | 9,072 | $2.48 | $22,498.56 |
DisclosureSEC source: 0001209191-22-022310 · doc4.xml · nonDerivative · entry 1 Doyle Ramona · CIK 0001856069 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,942 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 01:00 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,625 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001209191-22-014405 · doc4.xml · derivative · entry 2 Doyle Ramona · CIK 0001856069 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 678,428 Underlying: Class A Common Stock · 678,428 shares Expires 2030-12-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Twenty-Five percent (25%) of the 750,000 shares originally subject to the award shall vest one year after December 31, 2020, or the Vesting Commencement Date, and one-forty-eighth (148th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 01:00 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionClass A Common Stock | 15,625 | $2.48 | $38,750.00 |
DisclosureSEC source: 0001209191-22-014405 · doc4.xml · nonDerivative · entry 1 Doyle Ramona · CIK 0001856069 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,870 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 04, 2022 Filed Feb 9, 2022 02:09 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantStock Option (Right to Buy) · Derivative | 4,784 | $0.00 Strike: $11.40 | $0.00 |
DisclosureSEC source: 0001209191-22-007915 · doc4.xml · derivative · entry 5 Doyle Ramona · CIK 0001856069 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,784 Underlying: Class A Common Stock · 4,784 shares Expires 2032-02-04 Read SEC document |
| February 04, 2022 Filed Feb 9, 2022 02:09 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantStock Option (Right to Buy) · Derivative | 76,998 | $0.00 Strike: $11.40 | $0.00 |
DisclosureSEC source: 0001209191-22-007915 · doc4.xml · derivative · entry 4 Doyle Ramona · CIK 0001856069 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,998 Underlying: Class A Common Stock · 76,998 shares Expires 2032-02-04 F3 · derivative.exercise_date: The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. Read SEC document |
| February 04, 2022 Filed Feb 9, 2022 02:09 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 981 | $11.40 | $11,183.40 |
DisclosureSEC source: 0001209191-22-007915 · doc4.xml · nonDerivative · entry 3 Doyle Ramona · CIK 0001856069 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,245 Read SEC document |
| February 04, 2022 Filed Feb 9, 2022 02:09 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 2,392 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-007915 · doc4.xml · nonDerivative · entry 2 Doyle Ramona · CIK 0001856069 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,226 F2 · kind: This RSU vested immediately upon the grant date. Read SEC document |
| February 04, 2022 Filed Feb 9, 2022 02:09 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 38,499 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-007915 · doc4.xml · nonDerivative · entry 1 Doyle Ramona · CIK 0001856069 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,834 F1 · kind: This RSU vests as to one one-sixteenth (1/16th) of the units subject the RSU on May 15, 2022 and every three months thereafter. Read SEC document |
| January 31, 2022 Filed Feb 3, 2022 01:11 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,625 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001209191-22-006598 · doc4.xml · derivative · entry 2 Doyle Ramona · CIK 0001856069 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 694,053 Underlying: Class A Common Stock · 15,625 shares Expires 2030-12-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person. F3 · derivative.exercise_date: Twenty-Five percent (25%) of the 750,000 shares originally subject to the award shall vest one year after December 31, 2020, or the Vesting Commencement Date, and one-forty-eighth (148th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date. Read SEC document |
| January 31, 2022 Filed Feb 3, 2022 01:11 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionClass A Common Stock | 15,625 | $2.48 | $38,750.00 |
DisclosureSEC source: 0001209191-22-006598 · doc4.xml · nonDerivative · entry 1 Doyle Ramona · CIK 0001856069 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,335 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person. F2 · balance_after: Includes 1,388 shares purchased pursuant to the Issuer's Employee Stock Purchase Plan on November 22, 2021 Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 01:48 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionStock Option (Right to Buy) · Derivative | 40,322 | $0.00 Strike: $2.47 | $0.00 |
DisclosureSEC source: 0001209191-22-002062 · doc4.xml · derivative · entry 2 Doyle Ramona · CIK 0001856069 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 709,678 Underlying: Class A Common Stock · 40,322 shares Expires 2030-12-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person. F2 · derivative.exercise_date: Twenty-Five percent (25%) of the 750,000 shares originally subject to the award shall vest one year after December 31, 2020, or the Vesting Commencement Date, and one-forty-eighth (148th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 01:48 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionClass A Common Stock | 40,322 | $2.47 | $99,595.34 |
DisclosureSEC source: 0001209191-22-002062 · doc4.xml · nonDerivative · entry 1 Doyle Ramona · CIK 0001856069 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,322 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person. Read SEC document |
| April 20, 2021 Filed Apr 22, 2021 23:53 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionStock Option (Right to Buy) · Derivative | 750,000 | $0.00 Strike: $2.47 | $0.00 |
DisclosureSEC source: 0001209191-21-028028 · doc4.xml · derivative · entry 2 Doyle Ramona · CIK 0001856069 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750,000 Underlying: Class A Common Stock · 750,000 shares Expires 2030-12-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Twenty-Five percent (25%) of the shares subject to the award shall vest one year after December 31, 2020, or the Vesting Commencement Date, and one-forty-eighth (148th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date. F2 · derivative.underlying: Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO. Read SEC document |
| April 20, 2021 Filed Apr 22, 2021 23:53 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionStock Option (Right to Buy) · Derivative | 750,000 | $0.00 Strike: $2.47 | $0.00 |
DisclosureSEC source: 0001209191-21-028028 · doc4.xml · derivative · entry 1 Doyle Ramona · CIK 0001856069 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 750,000 shares Expires 2030-12-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Twenty-Five percent (25%) of the shares subject to the award shall vest one year after December 31, 2020, or the Vesting Commencement Date, and one-forty-eighth (148th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date. F2 · derivative.underlying: Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.